Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

Fred Saad, Allan Lipton

Research output: Contribution to journalShort survey

49 Citations (Scopus)

Abstract

Patients with metastatic bone disease often have severe bone pain and debilitating skeletal complications. Zoledronic acid is the only bisphosphonate shown to be safe and effective in reducing skeletal-related events (SREs), including pathological fractures, spinal cord compression, and radiation or surgery to bone in patients with bone metastases from advanced prostate cancer or renal cell carcinoma (RCC). In both tumour types, zoledronic acid significantly decreased the overall riskof developing an SRE, delayed their onset and significantly reduced the incidence of SREs compared with placebo. In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long-term use.

Original languageEnglish (US)
Pages (from-to)964-969
Number of pages6
JournalBJU International
Volume96
Issue number7
DOIs
StatePublished - Nov 1 2005

Fingerprint

zoledronic acid
Urogenital Neoplasms
Neoplasm Metastasis
Bone and Bones
Renal Cell Carcinoma
Placebos
Spontaneous Fractures
Spinal Cord Compression
Bone Diseases
Diphosphonates
Prostatic Neoplasms
Radiation
Pain
Incidence

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{dc61650e368140d794597fb3ad925859,
title = "Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers",
abstract = "Patients with metastatic bone disease often have severe bone pain and debilitating skeletal complications. Zoledronic acid is the only bisphosphonate shown to be safe and effective in reducing skeletal-related events (SREs), including pathological fractures, spinal cord compression, and radiation or surgery to bone in patients with bone metastases from advanced prostate cancer or renal cell carcinoma (RCC). In both tumour types, zoledronic acid significantly decreased the overall riskof developing an SRE, delayed their onset and significantly reduced the incidence of SREs compared with placebo. In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long-term use.",
author = "Fred Saad and Allan Lipton",
year = "2005",
month = "11",
day = "1",
doi = "10.1111/j.1464-410X.2005.05740.x",
language = "English (US)",
volume = "96",
pages = "964--969",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "7",

}

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. / Saad, Fred; Lipton, Allan.

In: BJU International, Vol. 96, No. 7, 01.11.2005, p. 964-969.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

AU - Saad, Fred

AU - Lipton, Allan

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Patients with metastatic bone disease often have severe bone pain and debilitating skeletal complications. Zoledronic acid is the only bisphosphonate shown to be safe and effective in reducing skeletal-related events (SREs), including pathological fractures, spinal cord compression, and radiation or surgery to bone in patients with bone metastases from advanced prostate cancer or renal cell carcinoma (RCC). In both tumour types, zoledronic acid significantly decreased the overall riskof developing an SRE, delayed their onset and significantly reduced the incidence of SREs compared with placebo. In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long-term use.

AB - Patients with metastatic bone disease often have severe bone pain and debilitating skeletal complications. Zoledronic acid is the only bisphosphonate shown to be safe and effective in reducing skeletal-related events (SREs), including pathological fractures, spinal cord compression, and radiation or surgery to bone in patients with bone metastases from advanced prostate cancer or renal cell carcinoma (RCC). In both tumour types, zoledronic acid significantly decreased the overall riskof developing an SRE, delayed their onset and significantly reduced the incidence of SREs compared with placebo. In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long-term use.

UR - http://www.scopus.com/inward/record.url?scp=27444444857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444444857&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2005.05740.x

DO - 10.1111/j.1464-410X.2005.05740.x

M3 - Short survey

C2 - 16225510

AN - SCOPUS:27444444857

VL - 96

SP - 964

EP - 969

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 7

ER -